27 Oct Advances in Scleroderma Treatment: What Patients Should Know
Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease that causes the body’s connective tissue to harden and tighten. While it often begins with skin changes, it can also affect internal organs such as the lungs, heart, kidneys, and digestive system. Living with scleroderma is challenging, but there’s good news: treatment options are improving every year.
In the past, scleroderma was viewed as an untreatable disease with limited hope. Today, thanks to medical research, new therapies, and better management strategies, patients have more options than ever before. This article explores the most important advances in scleroderma treatment and what patients and families should know moving forward.
Why Treatment Advances Matter
Scleroderma is a progressive disease, meaning it can worsen over time if not managed properly. Traditional treatments often focused only on controlling symptoms. But new approaches aim to:
- Slow or stop disease progression.
- Prevent organ damage.
- Reduce reliance on steroids.
- Improve quality of life and long-term outcomes.
This shift represents real hope for patients who once had very few options.
The Cornerstones of Traditional Treatment
Before diving into new advances, it helps to understand the traditional treatment approaches:
- Immunosuppressants: Drugs like methotrexate, azathioprine, and cyclophosphamide suppress the immune system to reduce inflammation.
- Steroids (corticosteroids): Useful in small doses for inflammation but risky in high doses due to side effects (and risk of scleroderma renal crisis).
- Supportive care: Proton pump inhibitors for reflux, vasodilators for Raynaud’s, and blood pressure control for kidney health.
While these treatments remain essential, the past decade has brought exciting advances that go beyond symptom relief.
Advances in Scleroderma Treatment
1. Antifibrotic Therapy
One of the hallmarks of scleroderma is fibrosis—the buildup of scar tissue in skin and organs. Until recently, no drug directly targeted this process.
- Nintedanib (Ofev): Originally approved for idiopathic pulmonary fibrosis, nintedanib was FDA-approved in 2019 for scleroderma-related interstitial lung disease (SSc-ILD).
- How it helps: Slows lung function decline by reducing fibrosis.
- What patients should know: It does not reverse scarring but may preserve lung capacity for longer.
This was a landmark approval because it was the first antifibrotic drug for scleroderma.
2. Biologic Therapies
Biologics are targeted treatments that block specific parts of the immune system instead of broadly suppressing it.
- Tocilizumab (Actemra): An IL-6 receptor blocker originally used for rheumatoid arthritis. In clinical trials, it showed promise in slowing lung disease in scleroderma.
- Rituximab: A B-cell–depleting therapy that may improve skin thickening and lung involvement. Though not yet FDA-approved specifically for scleroderma, it is used off-label in some centers.
- Abatacept: Blocks immune cell activation and is under investigation for skin and joint involvement.
What patients should know: Biologics may be considered if standard treatments are not enough, particularly in patients with lung or skin progression.
3. Stem Cell Transplantation
For patients with severe, rapidly progressing diffuse scleroderma, autologous stem cell transplantation (HSCT) is a groundbreaking option.
- How it works: High-dose chemotherapy wipes out the overactive immune system. Then, the patient’s own stem cells (collected beforehand) are infused back to “reboot” the immune system.
- Results: Studies show improved survival, reduced skin thickening, and slowed organ progression in carefully selected patients.
- Risks: HSCT carries significant risks, including infection and treatment-related mortality, so it is only offered at specialized centers.
What patients should know: This is not for everyone but can be life-changing for those with aggressive disease.
4. Pulmonary Hypertension Therapies
Pulmonary arterial hypertension (PAH) is one of the most serious complications of scleroderma. Advances in PAH treatments have dramatically improved survival.
- Endothelin receptor antagonists (ERAs): Bosentan, ambrisentan.
- Phosphodiesterase-5 inhibitors (PDE-5 inhibitors): Sildenafil, tadalafil.
- Prostacyclin analogs: Epoprostenol, treprostinil, iloprost.
- Soluble guanylate cyclase stimulators: Riociguat.
What patients should know: Early detection through echocardiograms and right-heart catheterization allows these treatments to be started sooner, improving outcomes.
5. Gastrointestinal Management Advances
GI involvement is very common in scleroderma, and new approaches are helping patients live more comfortably.
- Proton pump inhibitors (PPIs): Remain the standard for reflux, but newer surgical and endoscopic techniques are being explored.
- Prokinetic agents: Improve motility for patients with swallowing or intestinal issues.
- Antibiotics for SIBO (small intestinal bacterial overgrowth): Rotating antibiotics help manage bloating, diarrhea, and malabsorption.
- Nutrition support: Dieticians now play a larger role in managing scleroderma, tailoring food plans for reflux, motility, and nutrient absorption.
6. Digital Ulcer and Raynaud’s Management
Raynaud’s phenomenon and digital ulcers can be debilitating. Advances include:
- Topical therapies and vasodilators: Such as nitroglycerin ointment.
- Intravenous prostacyclin infusions: For severe Raynaud’s and non-healing ulcers.
- Botulinum toxin injections: A newer option that may improve blood flow to fingers.
7. Multi-Disciplinary Care
Perhaps one of the most important advances isn’t a single drug, but the shift toward specialized scleroderma centers and team-based care.
- Patients now benefit from care involving rheumatologists, pulmonologists, cardiologists, gastroenterologists, dermatologists, and physical therapists.
- Coordinated monitoring allows earlier intervention and improved survival.
What patients should know: If possible, consider being seen at a scleroderma specialty center, where the latest treatments and clinical trials are available.
Clinical Trials and the Future
Ongoing research is exploring:
- New antifibrotic drugs to prevent scarring in skin and lungs.
- Targeted biologics that block different immune pathways (such as IL-13 or TGF-beta).
- Precision medicine: Using genetic and antibody profiles to personalize treatment plans.
- Combination therapies: Testing whether multiple drugs together are more effective than one alone.
What patients should know: Participating in clinical trials can provide access to cutting-edge therapies and help advance knowledge for all patients.
Lifestyle and Self-Management Still Matter
Even with medical advances, daily lifestyle choices remain crucial in managing scleroderma. Patients should:
- Protect skin and joints with moisturizers and warmth.
- Avoid smoking, which worsens blood vessel and lung disease.
- Stay physically active with gentle, regular exercise.
- Eat a balanced diet that supports digestive health.
- Monitor blood pressure regularly to protect kidneys.
Key point: New treatments work best when paired with good self-care habits.
Questions Patients Should Ask Their Doctor
When discussing new treatments, patients may ask:
- Am I a candidate for antifibrotic therapy like nintedanib?
- Should I be screened for pulmonary hypertension, and how often?
- Could a biologic therapy help me?
- Is stem cell transplantation an option in my case?
- What lifestyle changes can I make to complement my treatment?
- Are there clinical trials I might qualify for?
Final Thoughts
Scleroderma remains a serious and complex autoimmune disease, but advances in treatment are changing the outlook. From antifibrotic drugs and biologics to improved management of lung and heart complications, patients now have more hope than ever before.
While there is still no cure, progress in slowing disease, preserving organ function, and improving quality of life is very real. With continued research and patient participation in clinical trials, the future looks brighter.
Takeaway: If you or a loved one has scleroderma, stay informed, ask questions, and consider care at a specialized center. The landscape of treatment is evolving quickly—and being proactive can make all the difference.
